Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death

• click to rate

  Posted by Two Blokes May 27, 2025 - Filed in Stock - 5 views
  
  Shares of Rocket Pharmaceuticals (NASDAQ:RCKT) sank nearly 60% on Tuesday morning after the company disclosed that the US Food and Drug Administration had placed a clinical hold on its pivotal Phase II trial for Danon disease, a rare genetic heart disorder, following the death of a patient in the study. The patient experienced a serious adverse event (SAE) of capillary leak syndrome and subsequently died due to an acute systemic infection, according to reports.